CNS Drugs

, Volume 16, Issue 7, pp 485–500

Cholinergic Nicotinic Systems in Alzheimer’s Disease

Prospects for Pharmacological Intervention
  • Robyn Vesey
  • Jennifer M. Birrell
  • Clare Bolton
  • Ruth S. Chipperfield
  • Andrew D. Blackwell
  • Tom R. Dening
  • Barbara J. Sahakian
Review Article

DOI: 10.2165/00023210-200216070-00005

Cite this article as:
Vesey, R., Birrell, J.M., Bolton, C. et al. Mol Diag Ther (2002) 16: 485. doi:10.2165/00023210-200216070-00005

Abstract

Within the last few years, research into the cause and progression of Alzheimer’s disease has made significant advances. Although there is still no preventative treatment or cure for this neurodegenerative illness, the development of drugs that may alleviate some of the cognitive symptoms associated with it is advancing. Cholinesterase inhibitors are at present the most effective form of treatment and have shown significant overall response rates in clinical trials. However, although some patients show substantial improvement when treated with this class of drugs, there is considerable variability in the amount of benefit gained in different individuals in terms of their cognitive and behavioural functioning. Furthermore, unfortunately some patients gain little or no benefit from these drugs. It would therefore be of great advantage to explore alternative therapeutic possibilities.

This article reviews the potential involvement of the nicotinic cholinergic system in Alzheimer’s disease and discusses the possibility of nicotinic pharmacotherapy. Substantial evidence indicates the involvement of the nicotinic cholinergic system in the pathology of Alzheimer’s disease. Drugs targeting these sites may not only have a positive effect on cognitive function, but also have additional therapeutic benefits in terms of restoring the hypoactivity in the excitatory amino acid pyramidal system and even slowing the emergence of Alzheimer’s disease pathology. The conclusion of this review is that nicotinic treatments are an important potential source of new therapeutic interventions in Alzheimer’s disease.

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Robyn Vesey
    • 1
  • Jennifer M. Birrell
    • 2
  • Clare Bolton
    • 1
  • Ruth S. Chipperfield
    • 3
  • Andrew D. Blackwell
    • 1
  • Tom R. Dening
    • 3
  • Barbara J. Sahakian
    • 1
  1. 1.Department of Psychiatry, University of Cambridge School of Clinical MedicineAddenbrooke’s HospitalCambridgeUK
  2. 2.Cambridge Cognition, BottishamCambridgeUK
  3. 3.Department of Psychiatric Services for the ElderlyFulbourn HospitalCambridgeUK